{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,27]],"date-time":"2026-08-27T17:59:13Z","timestamp":1787853553542,"version":"build-2784847793"},"publisher-location":"Cham","reference-count":97,"publisher":"Springer International Publishing","isbn-type":[{"value":"9783030504939","type":"print"},{"value":"9783030504946","type":"electronic"}],"license":[{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"},{"start":{"date-parts":[[2019,1,1]],"date-time":"2019-01-01T00:00:00Z","timestamp":1546300800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019]]},"DOI":"10.1007\/164_2019_263","type":"book-chapter","created":{"date-parts":[[2019,8,26]],"date-time":"2019-08-26T07:02:44Z","timestamp":1566802964000},"page":"39-56","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Current and Emerging Therapies for Mucopolysaccharidoses"],"prefix":"10.1007","author":[{"given":"Florian B.","family":"Lagler","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2019,8,27]]},"reference":[{"key":"263_CR1","doi-asserted-by":"crossref","first-page":"860","DOI":"10.3109\/14653249.2012.672730","volume":"14","author":"G Baldo","year":"2012","unstructured":"Baldo G, Mayer FQ, Martinelli B, Meyer FS, Burin M, Meurer L, Tavares AMV, Giugliani R, Matte U (2012) Intraperitoneal implant of recombinant encapsulated cells overexpressing alpha-L-iduronidase partially corrects visceral pathology in mucopolysaccharidosis type I mice. Cytotherapy 14:860\u2013867","journal-title":"Cytotherapy"},{"key":"263_CR2","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1517\/17425247.2014.880689","volume":"11","author":"G Baldo","year":"2014","unstructured":"Baldo G, Giugliani R, Matte U (2014) Gene delivery strategies for the treatment of mucopolysaccharidoses. Expert Opin Drug Deliv 11:449\u2013459","journal-title":"Expert Opin Drug Deliv"},{"key":"263_CR3","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/s00005-012-0195-9","volume":"60","author":"Z Banecka-Majkutewicz","year":"2012","unstructured":"Banecka-Majkutewicz Z, Jakobkiewicz-Banecka J, Gabig-Ciminska M, Wegrzyn A, Wegrzyn G (2012) Putative biological mechanisms of efficiency of substrate reduction therapies for mucopolysaccharidoses. Arch Immunol Ther Exp 60:461\u2013468","journal-title":"Arch Immunol Ther Exp"},{"key":"263_CR4","doi-asserted-by":"crossref","first-page":"363","DOI":"10.1007\/s10545-012-9521-y","volume":"36","author":"R Bartolomeo","year":"2013","unstructured":"Bartolomeo R, Polishchuk EV, Volpi N, Polishchuk RS, Auricchio A (2013) Pharmacological read-through of nonsense ARSB mutations as a potential therapeutic approach for mucopolysaccharidosis VI. J Inherit Metab Dis 36:363\u2013371","journal-title":"J Inherit Metab Dis"},{"key":"263_CR5","doi-asserted-by":"crossref","first-page":"1233158","DOI":"10.1126\/science.1233158","volume":"341","author":"A Biffi","year":"2013","unstructured":"Biffi A, Montini E, Lorioli L, Cesani M, Fumagalli F, Plati T, Baldoli C, Martino S, Calabria A, Canale S et al (2013) Lentiviral hematopoietic stem cell gene therapy benefits metachromatic leukodystrophy. Science 341:1233158","journal-title":"Science"},{"key":"263_CR6","doi-asserted-by":"crossref","first-page":"1271","DOI":"10.1021\/acs.molpharmaceut.6b01166","volume":"14","author":"RJ Boado","year":"2017","unstructured":"Boado RJ, Pardridge WM (2017) Brain and organ uptake in the rhesus monkey in vivo of recombinant iduronidase compared to an insulin receptor antibody-iduronidase fusion protein. Mol Pharm 14:1271\u20131277","journal-title":"Mol Pharm"},{"key":"263_CR7","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1124\/dmd.112.046375","volume":"40","author":"RJ Boado","year":"2012","unstructured":"Boado RJ, Hui EK, Lu JZ, Pardridge WM (2012) Glycemic control and chronic dosing of rhesus monkeys with a fusion protein of iduronidase and a monoclonal antibody against the human insulin receptor. Drug Metab Dispos 40:2021\u20132025","journal-title":"Drug Metab Dispos"},{"key":"263_CR8","doi-asserted-by":"crossref","first-page":"2317","DOI":"10.1002\/bit.25289","volume":"111","author":"RJ Boado","year":"2014","unstructured":"Boado RJ, Ka-Wai Hui E, Zhiqiang Lu J, Pardridge WM (2014a) Insulin receptor antibody-iduronate 2-sulfatase fusion protein: pharmacokinetics, anti-drug antibody, and safety pharmacology in Rhesus monkeys. Biotechnol Bioeng 111:2317\u20132325","journal-title":"Biotechnol Bioeng"},{"key":"263_CR9","doi-asserted-by":"crossref","first-page":"2928","DOI":"10.1021\/mp500258p","volume":"11","author":"RJ Boado","year":"2014","unstructured":"Boado RJ, Lu JZ, Hui EK, Pardridge WM (2014b) Insulin receptor antibody-sulfamidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in Sanfilippo type A cells. Mol Pharm 11:2928\u20132934","journal-title":"Mol Pharm"},{"key":"263_CR10","doi-asserted-by":"crossref","first-page":"1385","DOI":"10.1021\/acs.molpharmaceut.6b00037","volume":"13","author":"RJ Boado","year":"2016","unstructured":"Boado RJ, Lu JZ, Hui EK, Lin H, Pardridge WM (2016) Insulin receptor antibody-alpha-N-acetylglucosaminidase fusion protein penetrates the primate blood-brain barrier and reduces glycosoaminoglycans in sanfilippo type B fibroblasts. Mol Pharm 13:1385\u20131392","journal-title":"Mol Pharm"},{"issue":"2","key":"263_CR11","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1021\/acs.molpharmaceut.7b00958","volume":"15","author":"RJ Boado","year":"2017","unstructured":"Boado RJ, Lu JZ, Hui EK, Pardridge WM (2017) Reduction in brain heparan sulfate with systemic administration of an IgG trojan horse-sulfamidase fusion protein in the mucopolysaccharidosis type IIIA mouse. Mol Pharm 15(2):602\u2013608","journal-title":"Mol Pharm"},{"key":"263_CR97","doi-asserted-by":"crossref","first-page":"312","DOI":"10.1056\/NEJM196608112750606","volume":"275","author":"RO Brady","year":"1966","unstructured":"Brady RO (1966) The sphingolipidoses. N Engl J Med 275:312\u2013318","journal-title":"N Engl J Med"},{"key":"263_CR12","doi-asserted-by":"crossref","first-page":"2272","DOI":"10.1002\/ajmg.a.37172","volume":"167a","author":"BK Burton","year":"2015","unstructured":"Burton BK, Berger KI, Lewis GD, Tarnopolsky M, Treadwell M, Mitchell JJ, Muschol N, Jones SA, Sutton VR, Pastores GM et al (2015) Safety and physiological effects of two different doses of elosulfase alfa in patients with morquio a syndrome: a randomized, double-blind, pilot study. Am J Med Genet A 167a:2272\u20132281","journal-title":"Am J Med Genet A"},{"key":"263_CR13","unstructured":"Clinicaltrials.gov (2017) Study of intrathecal idursulfase-IT administered in conjunction with elaprase in pediatric patients with hunter syndrome and early cognitive impairment. \nhttps:\/\/clinicaltrials.gov\/ct2\/show\/study\/NCT02055118"},{"key":"263_CR14","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1002\/ana.22643","volume":"71","author":"J de Ruijter","year":"2012","unstructured":"de Ruijter J, Valstar MJ, Narajczyk M, Wegrzyn G, Kulik W, Ijlst L, Wagemans T, van der Wal WM, Wijburg FA (2012) Genistein in Sanfilippo disease: a randomized controlled crossover trial. Ann Neurol 71:110\u2013120","journal-title":"Ann Neurol"},{"key":"263_CR96","unstructured":"De Duve C (1964) From cytases to lysosomes. Fed Proc:1045\u20131049"},{"key":"263_CR15","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s10545-011-9342-4","volume":"34","author":"V Delgadillo","year":"2011","unstructured":"Delgadillo V, O\u2019Callaghan Mdel M, Artuch R, Montero R, Pineda M (2011) Genistein supplementation in patients affected by Sanfilippo disease. J Inherit Metab Dis 34:1039\u20131044","journal-title":"J Inherit Metab Dis"},{"key":"263_CR16","doi-asserted-by":"crossref","first-page":"5","DOI":"10.3390\/diseases5010005","volume":"5","author":"ALK Derrick-Roberts","year":"2017","unstructured":"Derrick-Roberts ALK, Jackson MR, Pyragius CE, Byers S (2017) Substrate deprivation therapy to reduce glycosaminoglycan synthesis improves aspects of neurological and skeletal pathology in MPS I mice. Diseases 5:5","journal-title":"Diseases"},{"key":"263_CR17","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1016\/j.ymgme.2006.12.012","volume":"91","author":"P Dickson","year":"2007","unstructured":"Dickson P, McEntee M, Vogler C, Le S, Levy B, Peinovich M, Hanson S, Passage M, Kakkis E (2007) Intrathecal enzyme replacement therapy: successful treatment of brain disease via the cerebrospinal fluid. Mol Genet Metab 91:61\u201368","journal-title":"Mol Genet Metab"},{"key":"263_CR18","doi-asserted-by":"crossref","first-page":"69","DOI":"10.1016\/j.ymgme.2015.07.005","volume":"116","author":"PI Dickson","year":"2015","unstructured":"Dickson PI, Kaitila I, Harmatz P, Mlikotic A, Chen AH, Victoroff A, Passage MB, Madden J, Le SQ, Naylor DE (2015) Safety of laronidase delivered into the spinal canal for treatment of cervical stenosis in mucopolysaccharidosis I. Mol Genet Metab 116:69\u201374","journal-title":"Mol Genet Metab"},{"key":"263_CR19","doi-asserted-by":"crossref","first-page":"60ra89","DOI":"10.1126\/scitranslmed.3001380","volume":"2","author":"AD Dierenfeld","year":"2010","unstructured":"Dierenfeld AD, McEntee MF, Vogler CA, Vite CH, Chen AH, Passage M, Le S, Shah S, Jens JK, Snella EM et al (2010) Replacing the enzyme alpha-L-iduronidase at birth ameliorates symptoms in the brain and periphery of dogs with mucopolysaccharidosis type I. Sci Transl Med 2:60ra89","journal-title":"Sci Transl Med"},{"key":"263_CR20","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1002\/jgm.581","volume":"6","author":"NM Ellinwood","year":"2004","unstructured":"Ellinwood NM, Vite CH, Haskins ME (2004) Gene therapy for lysosomal storage diseases: the lessons and promise of animal models. J Gene Med 6:481\u2013506","journal-title":"J Gene Med"},{"key":"263_CR21","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1038\/mt.2010.265","volume":"19","author":"NM Ellinwood","year":"2011","unstructured":"Ellinwood NM, Ausseil J, Desmaris N, Bigou S, Liu S, Jens JK, Snella EM, Mohammed EE, Thomson CB, Raoul S (2011) Safe, efficient, and reproducible gene therapy of the brain in the dog models of Sanfilippo and Hurler syndromes. Mol Ther 19:251\u2013259","journal-title":"Mol Ther"},{"key":"263_CR22","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1016\/j.ymgme.2010.03.019","volume":"100","author":"K Fantur","year":"2010","unstructured":"Fantur K, Hofer D, Schitter G, Steiner AJ, Pabst BM, Wrodnigg TM, Stutz AE, Paschke E (2010) DLHex-DGJ, a novel derivative of 1-deoxygalactonojirimycin with pharmacological chaperone activity in human G(M1)-gangliosidosis fibroblasts. Mol Genet Metab 100:262\u2013268","journal-title":"Mol Genet Metab"},{"key":"263_CR23","doi-asserted-by":"crossref","first-page":"S46","DOI":"10.1016\/j.ymgme.2017.12.103","volume":"123","author":"K Flanigan","year":"2018","unstructured":"Flanigan K, Truxal K, McBride K, McNally K, Kunkler K, Zumberge N, Martin L, Aylward S, Corridore M, Ruiz J et al (2018) A phase 1\/2 clinical trial of systemic gene transfer of scAAV9.U1a.HSGSH for MPS IIIA: safety, tolerability, and preliminary evidence of biopotency. Mol Genet Metab 123:S46","journal-title":"Mol Genet Metab"},{"key":"263_CR24","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1126\/science.162.3853.570","volume":"162","author":"JC Fratantoni","year":"1968","unstructured":"Fratantoni JC, Hall CW, Neufeld EF (1968) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162:570\u2013572","journal-title":"Science"},{"key":"263_CR25","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1002\/jgm.790","volume":"7","author":"A Friso","year":"2005","unstructured":"Friso A, Tomanin R, Alba S, Gasparotto N, Puicher EP, Fusco M, Hortelano G, Muenzer J, Marin O, Zacchello F (2005) Reduction of GAG storage in MPS II mouse model following implantation of encapsulated recombinant myoblasts. J Gene Med 7:1482\u20131491","journal-title":"J Gene Med"},{"key":"263_CR26","doi-asserted-by":"crossref","first-page":"e100882","DOI":"10.1371\/journal.pone.0100882","volume":"9","author":"M Frohbergh","year":"2014","unstructured":"Frohbergh M, Ge Y, Meng F, Karabul N, Solyom A, Lai A, Iatridis J, Schuchman EH, Simonaro CM (2014) Dose responsive effects of subcutaneous pentosan polysulfate injection in mucopolysaccharidosis type VI rats and comparison to oral treatment. PLoS One 9:e100882","journal-title":"PLoS One"},{"key":"263_CR27","first-page":"53","volume":"2","author":"R Giugliani","year":"2012","unstructured":"Giugliani R et al (2012) Emerging treatment options for the mucopolysaccharidoses. Res Rep Endocr Disord 2:53\u201364","journal-title":"Res Rep Endocr Disord"},{"key":"263_CR28","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1016\/j.ymgme.2017.12.126","volume":"123","author":"L Giugliani","year":"2018","unstructured":"Giugliani L, Carvalho Doni K, Poswar F, Giugliani R, Boado R (2018a) Somatic effects of AGT-181 in patients with mucopolysaccharidosis I enrolled in a phase I\/II clinical trial in Brazil. Mol Genet Metab 123:S53","journal-title":"Mol Genet Metab"},{"key":"263_CR29","first-page":"S54","volume":"123","author":"R Giugliani","year":"2018","unstructured":"Giugliani R, Giugliani L, Dalle Corte A, Poswar F, Donis K, Schmidt M, Hunt D, Boado RJ (2018b) Safety and clinical efficacy of AGT-181, a brain penetrating human insulin receptor antibody-iduronidase fusion protein, in a 26-week study with pediatric patients with mucopolysaccharidosis type I. Mol Genet Metab 123:S54","journal-title":"Mol Genet Metab"},{"key":"263_CR30","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1039\/9781782624202-00164","volume-title":"Orphan drugs and rare diseases","author":"MW Heartlein","year":"2014","unstructured":"Heartlein MW, Kimura A (2014) Discovery and clinical development of idursulfase (Elaprase\u00ae) for the treatment of mucopolysaccharidosis II (Hunter syndrome). In: Pryde DC, Palmer M (eds) Orphan drugs and rare diseases. Royal Society of Chemistry, London, pp 164\u2013182"},{"key":"263_CR31","doi-asserted-by":"crossref","first-page":"453","DOI":"10.1016\/j.jmb.2004.03.012","volume":"338","author":"LK Hein","year":"2004","unstructured":"Hein LK, Bawden M, Muller VJ, Sillence D, Hopwood JJ, Brooks DA (2004) \u03b1-L-iduronidase premature stop codons and potential read-through in mucopolysaccharidosis type I patients. J Mol Biol 338:453\u2013462","journal-title":"J Mol Biol"},{"key":"263_CR32","doi-asserted-by":"crossref","first-page":"1521","DOI":"10.1080\/17512433.2017.1260000","volume":"9","author":"CJ Hendriksz","year":"2016","unstructured":"Hendriksz CJ (2016) Elosulfase alfa (BMN 110) for the treatment of mucopolysaccharidosis IVA (Morquio A Syndrome). Expert Rev Clin Pharmacol 9:1521\u20131532","journal-title":"Expert Rev Clin Pharmacol"},{"key":"263_CR33","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10545-016-9974-5","volume":"39","author":"JB Hennermann","year":"2016","unstructured":"Hennermann JB, Gokce S, Solyom A, Mengel E, Schuchman EH, Simonaro CM (2016) Treatment with pentosan polysulphate in patients with MPS I: results from an open label, randomized, monocentric phase II study. J Inherit Metab Dis 39:831\u2013837","journal-title":"J Inherit Metab Dis"},{"key":"263_CR34","doi-asserted-by":"crossref","first-page":"124","DOI":"10.1016\/j.ymgme.2016.06.006","volume":"119","author":"C Hinderer","year":"2016","unstructured":"Hinderer C, Bell P, Louboutin JP, Katz N, Zhu Y, Lin G, Choa R, Bagel J, O\u2019Donnell P, Fitzgerald CA et al (2016) Neonatal tolerance induction enables accurate evaluation of gene therapy for MPS I in a canine model. Mol Genet Metab 119:124\u2013130","journal-title":"Mol Genet Metab"},{"key":"263_CR35","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1093\/brain\/awx311","volume":"141","author":"RJ Holley","year":"2018","unstructured":"Holley RJ, Ellison SM, Fil D, O\u2019Leary C, McDermott J, Senthivel N, Langford-Smith AWW, Wilkinson FL, D\u2019Souza Z, Parker H et al (2018) Macrophage enzyme and reduced inflammation drive brain correction of mucopolysaccharidosis IIIB by stem cell gene therapy. Brain 141:99\u2013116","journal-title":"Brain"},{"key":"263_CR36","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1016\/j.jpeds.2014.09.023","volume":"166","author":"PV Hopkins","year":"2015","unstructured":"Hopkins PV, Campbell C, Klug T, Rogers S, Raburn-Miller J, Kiesling J (2015) Lysosomal storage disorder screening implementation: findings from the first six months of full population pilot testing in Missouri. J Pediatr 166:172\u2013177","journal-title":"J Pediatr"},{"key":"263_CR37","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1016\/j.ymgme.2017.12.428","volume":"123","author":"H Hoshina","year":"2018","unstructured":"Hoshina H, Shimada Y, Higuchi T, Kobayashi H, Ida H, Ohashi T (2018) Chaperone effect of sulfated disaccharide from heparin on mutant iduronate-2-sulfatase in mucopolysaccharidosis type II. Mol Genet Metab 123:118\u2013122","journal-title":"Mol Genet Metab"},{"key":"263_CR38","first-page":"104","volume":"10","author":"C Hunter","year":"1917","unstructured":"Hunter C (1917) A rare disease in two brothers. Proc R Soc Med 10:104\u2013116","journal-title":"Proc R Soc Med"},{"key":"263_CR39","doi-asserted-by":"crossref","first-page":"220","DOI":"10.1007\/BF02222956","volume":"24","author":"G Hurler","year":"1920","unstructured":"Hurler G (1920) \u00dcber einen Typ multipler Abartungen, vorwiegend am Skelettsystem. Z Kinderheilkd 24:220\u2013234","journal-title":"Z Kinderheilkd"},{"key":"263_CR40","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1016\/j.ymgme.2016.05.006","volume":"118","author":"SA Jones","year":"2016","unstructured":"Jones SA, Breen C, Heap F, Rust S, de Ruijter J, Tump E, Marchal JP, Pan L, Qiu Y, Chung JK et al (2016) A phase 1\/2 study of intrathecal heparan-N-sulfatase in patients with mucopolysaccharidosis IIIA. Mol Genet Metab 118:198\u2013205","journal-title":"Mol Genet Metab"},{"key":"263_CR41","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1016\/j.ymgme.2004.07.003","volume":"83","author":"E Kakkis","year":"2004","unstructured":"Kakkis E, McEntee M, Vogler C, Le S, Levy B, Belichenko P, Mobley W, Dickson P, Hanson S, Passage M (2004) Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS I. Mol Genet Metab 83:163\u2013174","journal-title":"Mol Genet Metab"},{"key":"263_CR42","first-page":"139","volume-title":"JIMD reports \u2013 case and research reports","author":"M Kamei","year":"2013","unstructured":"Kamei M, Kasperski K, Fuller M, Parkinson-Lawrence EJ, Karageorgos L, Belakhov V, Baasov T, Hopwood JJ, Brooks DA (2013) Aminoglycoside-induced premature stop codon read-through of mucopolysaccharidosis type I patient Q70X and W402X mutations in cultured cells. In: JIMD reports \u2013 case and research reports, vol 13. Springer, Berlin, pp 139\u2013147"},{"key":"263_CR43","doi-asserted-by":"crossref","first-page":"14870","DOI":"10.1073\/pnas.1416660111","volume":"111","author":"SH Kan","year":"2014","unstructured":"Kan SH, Aoyagi-Scharber M, Le SQ, Vincelette J, Ohmi K, Bullens S, Wendt DJ, Christianson TM, Tiger PM, Brown JR et al (2014) Delivery of an enzyme-IGFII fusion protein to the mouse brain is therapeutic for mucopolysaccharidosis type IIIB. Proc Natl Acad Sci U S A 111:14870\u201314875","journal-title":"Proc Natl Acad Sci U S A"},{"key":"263_CR44","doi-asserted-by":"crossref","first-page":"e60478","DOI":"10.1371\/journal.pone.0060478","volume":"8","author":"KM Keeling","year":"2013","unstructured":"Keeling KM, Wang D, Dai Y, Murugesan S, Chenna B, Clark J, Belakhov V, Kandasamy J, Velu SE, Baasov T (2013) Attenuation of nonsense-mediated mRNA decay enhances in vivo nonsense suppression. PLoS One 8:e60478","journal-title":"PLoS One"},{"key":"263_CR45","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1016\/j.ymgme.2013.06.012","volume":"109","author":"KH Kim","year":"2013","unstructured":"Kim KH, Dodsworth C, Paras A, Burton BK (2013) High dose genistein aglycone therapy is safe in patients with mucopolysaccharidoses involving the central nervous system. Mol Genet Metab 109:382\u2013385","journal-title":"Mol Genet Metab"},{"key":"263_CR46","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ymgme.2017.06.001","volume":"122","author":"S Kim","year":"2017","unstructured":"Kim S, Whitley CB, Jarnes Utz JR (2017) Correlation between urinary GAG and anti-idursulfase ERT neutralizing antibodies during treatment with NICIT immune tolerance regimen: a case report. Mol Genet Metab 122:92\u201399","journal-title":"Mol Genet Metab"},{"key":"263_CR47","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1111\/jnc.13533","volume":"137","author":"B King","year":"2016","unstructured":"King B, Hassiotis S, Rozaklis T, Beard H, Trim PJ, Snel MF, Hopwood JJ, Hemsley KM (2016) Low-dose, continuous enzyme replacement therapy ameliorates brain pathology in the neurodegenerative lysosomal disorder mucopolysaccharidosis type IIIA. J Neurochem 137:409\u2013422","journal-title":"J Neurochem"},{"key":"263_CR48","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1007\/s10545-016-9994-1","volume":"40","author":"B King","year":"2017","unstructured":"King B, Marshall NR, Hassiotis S, Trim PJ, Tucker J, Hattersley K, Snel MF, Jolly RD, Hopwood JJ, Hemsley KM (2017) Slow, continuous enzyme replacement via spinal CSF in dogs with the paediatric-onset neurodegenerative disease, MPS IIIA. J Inherit Metab Dis 40:443\u2013453","journal-title":"J Inherit Metab Dis"},{"key":"263_CR49","doi-asserted-by":"crossref","first-page":"383","DOI":"10.3109\/02652048.2012.746745","volume":"30","author":"VL Lagranha","year":"2013","unstructured":"Lagranha VL, de Carvalho TG, Giugliani R, Matte U (2013) Treatment of MPS I mice with microencapsulated cells overexpressing IDUA: effect of the prednisolone administration. J Microencapsul 30:383\u2013389","journal-title":"J Microencapsul"},{"issue":"6","key":"263_CR50","doi-asserted-by":"crossref","first-page":"2289","DOI":"10.1016\/j.jaci.2017.12.1001","volume":"141","author":"M Lenders","year":"2018","unstructured":"Lenders M, Schmitz B, Brand SM, Foell D, Brand E (2018) Characterization of drug-neutralizing antibodies in patients with Fabry disease during infusion. J Allergy Clin Immunol 141(6):2289\u20132292","journal-title":"J Allergy Clin Immunol"},{"key":"263_CR51","doi-asserted-by":"crossref","first-page":"1146","DOI":"10.1007\/s10545-005-0211-x","volume":"28","author":"HY Lin","year":"2005","unstructured":"Lin HY, Lin SP, Chuang CK, Chen MR, Chen BF, Wraith JE (2005) Mucopolysaccharidosis I under enzyme replacement therapy with laronidase--a mortality case with autopsy report. J Inherit Metab Dis 28:1146\u20131148","journal-title":"J Inherit Metab Dis"},{"key":"263_CR52","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1007\/s10856-017-5844-4","volume":"28","author":"V Lizzi Lagranha","year":"2017","unstructured":"Lizzi Lagranha V, Zambiasi Martinelli B, Baldo G, Avila Testa G, Giacomet de Carvalho T, Giugliani R, Matte U (2017) Subcutaneous implantation of microencapsulated cells overexpressing alpha-L-iduronidase for mucopolysaccharidosis type I treatment. J Mater Sci Mater Med 28:43","journal-title":"J Mater Sci Mater Med"},{"key":"263_CR53","doi-asserted-by":"crossref","first-page":"e14192","DOI":"10.1371\/journal.pone.0014192","volume":"5","author":"M Malinowska","year":"2010","unstructured":"Malinowska M, Wilkinson FL, Langford-Smith KJ, Langford-Smith A, Brown JR, Crawford BE, Vanier MT, Grynkiewicz G, Wynn RF, Wraith JE et al (2010) Genistein improves neuropathology and corrects behaviour in a mouse model of neurodegenerative metabolic disease. PLoS One 5:e14192","journal-title":"PLoS One"},{"key":"263_CR54","first-page":"1849","volume":"71","author":"P Maroteaux","year":"1963","unstructured":"Maroteaux P, Leveque B, Marie J, Lamy M (1963) A new dysostosis with urinary elimination of chondroitin sulfate B. Presse Med 71:1849\u20131852","journal-title":"Presse Med"},{"key":"263_CR55","first-page":"122","volume":"2","author":"JJ Martin","year":"1983","unstructured":"Martin JJ, Ceuterick C (1983) Prenatal pathology in mucopolysaccharidoses: a comparison with postnatal cases. Clin Neuropathol 2:122\u2013127","journal-title":"Clin Neuropathol"},{"key":"263_CR56","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1186\/s13023-014-0180-y","volume":"9","author":"L Matos","year":"2014","unstructured":"Matos L, Canals I, Dridi L, Choi Y, Prata MJ, Jordan P, Desviat LR, Perez B, Pshezhetsky AV, Grinberg D et al (2014) Therapeutic strategies based on modified U1 snRNAs and chaperones for Sanfilippo C splicing mutations. Orphanet J Rare Dis 9:180","journal-title":"Orphanet J Rare Dis"},{"key":"263_CR57","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1007\/s11095-014-1508-y","volume":"32","author":"FQ Mayer","year":"2015","unstructured":"Mayer FQ, Adorne MD, Bender EA, de Carvalho TG, Dilda AC, Beck RCR, Guterres SS, Giugliani R, Matte U, Pohlmann AR (2015) Laronidase-functionalized multiple-wall lipid-core nanocapsules: promising formulation for a more effective treatment of mucopolysaccharidosis type I. Pharm Res 32:941\u2013954","journal-title":"Pharm Res"},{"key":"263_CR58","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/S0140-6736(11)61266-X","volume":"379","author":"TP Mechtler","year":"2012","unstructured":"Mechtler TP, Stary S, Metz TF, De Jesus VR, Greber-Platzer S, Pollak A, Herkner KR, Streubel B, Kasper DC (2012) Neonatal screening for lysosomal storage disorders: feasibility and incidence from a nationwide study in Austria. Lancet 379:335\u2013341","journal-title":"Lancet"},{"key":"263_CR59","first-page":"129","volume":"32","author":"L Morquio","year":"1929","unstructured":"Morquio L (1929) Sur une forme de dystrophie osseuse familialeArchives de medecine des infants. Arch Med Enfants 32:129\u2013135","journal-title":"Arch Med Enfants"},{"key":"263_CR60","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1038\/gim.2015.36","volume":"18","author":"J Muenzer","year":"2016","unstructured":"Muenzer J, Hendriksz CJ, Fan Z, Vijayaraghavan S, Perry V, Santra S, Solanki GA, Mascelli MA, Pan L, Wang N et al (2016) A phase I\/II study of intrathecal idursulfase-IT in children with severe mucopolysaccharidosis II. Genet Med 18:73\u201381","journal-title":"Genet Med"},{"key":"263_CR61","volume-title":"13th annual WORLD symposium, San Diego","author":"J Muenzer","year":"2017","unstructured":"Muenzer J et al (2017) A long-term extension study evaluating intrathecal idursulfase-IT in children with hunter syndrome and cognitive impairment. In: 13th annual WORLD symposium, San Diego"},{"key":"263_CR62","doi-asserted-by":"crossref","first-page":"S99","DOI":"10.1016\/j.ymgme.2017.12.262","volume":"123","author":"J Muenzer","year":"2018","unstructured":"Muenzer J, Burton BK, Harmatz P, Guti\u00e9rrez-Solana LG, Ruiz-Garcia M, Jones SA, Guffon N, Inbar-Feigenberg M, Bratkovic D, Wu Y et al (2018) Efficacy and safety of intrathecal idursulfase in pediatric patients with mucopolysaccharidosis type II and early cognitive impairment: design and methods of a controlled, randomized, phase II\/III multicenter study. Mol Genet Metab 123:S99\u2013S100","journal-title":"Mol Genet Metab"},{"key":"263_CR63","first-page":"549","volume":"68","author":"A M\u00fchlstein","year":"2013","unstructured":"M\u00fchlstein A, Gelperina S, Kreuter J (2013) Development of nanoparticle-bound arylsulfatase B for enzyme replacement therapy of mucopolysaccharidosis VI. Pharmazie 68:549\u2013554","journal-title":"Pharmazie"},{"key":"263_CR64","doi-asserted-by":"crossref","first-page":"2538","DOI":"10.1002\/ajmg.a.32294","volume":"146a","author":"MV Munoz-Rojas","year":"2008","unstructured":"Munoz-Rojas MV, Vieira T, Costa R, Fagondes S, John A, Jardim LB, Vedolin LM, Raymundo M, Dickson PI, Kakkis E et al (2008) Intrathecal enzyme replacement therapy in a patient with mucopolysaccharidosis type I and symptomatic spinal cord compression. Am J Med Genet A 146a:2538\u20132544","journal-title":"Am J Med Genet A"},{"key":"263_CR65","doi-asserted-by":"crossref","first-page":"S102","DOI":"10.1016\/j.ymgme.2017.12.270","volume":"123","author":"N Muschol","year":"2018","unstructured":"Muschol N, Cleary M, Couce ML, Shaywitz AJ, Cahan H, Grover A, Maricich SM, Melton A, Smith L, de Castro Lopez MJ (2018) ICV-administered BMN 250 (NAGLU-IGF2) is well tolerated and reduces heparan sulfate accumulation in the CNS of subjects with Sanfilippo syndrome type B (MPS IIIB). Mol Genet Metab 123:S102","journal-title":"Mol Genet Metab"},{"key":"263_CR66","first-page":"3421","volume-title":"The metabolic and molecular basis of inherited disease","author":"EMJ Neufeld","year":"2001","unstructured":"Neufeld EMJ (2001) The mucopolysaccharidosis. In: Scriver CBA, Sly S et al (eds) The metabolic and molecular basis of inherited disease. McGraw-Hill, New York, pp 3421\u20133452"},{"key":"263_CR67","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1111\/jcpt.12136","volume":"39","author":"H Noh","year":"2014","unstructured":"Noh H, Lee JI (2014) Current and potential therapeutic strategies for mucopolysaccharidoses. J Clin Pharm Ther 39:215\u2013224","journal-title":"J Clin Pharm Ther"},{"key":"263_CR68","doi-asserted-by":"crossref","first-page":"Cr196","DOI":"10.12659\/MSM.881715","volume":"17","author":"E Piotrowska","year":"2011","unstructured":"Piotrowska E, Jakobkiewicz-Banecka J, Maryniak A, Tylki-Szymanska A, Puk E, Liberek A, Wegrzyn A, Czartoryska B, Slominska-Wojewodzka M, Wegrzyn G (2011) Two-year follow-up of Sanfilippo Disease patients treated with a genistein-rich isoflavone extract: assessment of effects on cognitive functions and general status of patients. Med Sci Monit 17:Cr196\u2013Cr202","journal-title":"Med Sci Monit"},{"key":"263_CR69","doi-asserted-by":"crossref","first-page":"S121","DOI":"10.1016\/j.ymgme.2017.12.329","volume":"123","author":"AV Pshezhetsky","year":"2018","unstructured":"Pshezhetsky AV, Pan X, H\u00e9on-Roberts R, Li S-G, Wu HY, Taherzadeh M, De Arag\u00e3o CDBP, Wood J, Ekins S, Boyd R et al (2018) Chaperone therapy for mucopolysaccharidosis type IIIC. Mol Genet Metab 123:S121\u2013S122","journal-title":"Mol Genet Metab"},{"key":"263_CR70","doi-asserted-by":"crossref","first-page":"1137","DOI":"10.1007\/s40262-014-0173-y","volume":"53","author":"Y Qi","year":"2014","unstructured":"Qi Y, Musson DG, Schweighardt B, Tompkins T, Jesaitis L, Shaywitz AJ, Yang K, O\u2019Neill CA (2014) Pharmacokinetic and pharmacodynamic evaluation of elosulfase alfa, an enzyme replacement therapy in patients with Morquio A syndrome. Clin Pharmacokinet 53:1137\u20131147","journal-title":"Clin Pharmacokinet"},{"key":"263_CR71","first-page":"194","volume":"14","author":"F Quoos Mayer","year":"2013","unstructured":"Quoos Mayer F, Alfonso Artigalas O, Lizzi Lagranha V, Baldo G, Vanessa Schwartz I, Matte U, Giugliani R (2013) Chloramphenicol enhances IDUA activity on fibroblasts from mucopolysaccharidosis I patients. Curr Pharm Biotechnol 14:194\u2013198","journal-title":"Curr Pharm Biotechnol"},{"key":"263_CR72","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1203\/01.pdr.0000233037.00707.da","volume":"60","author":"AL Roberts","year":"2006","unstructured":"Roberts AL, Thomas BJ, Wilkinson AS, Fletcher JM, Byers S (2006) Inhibition of glycosaminoglycan synthesis using rhodamine B in a mouse model of mucopolysaccharidosis type IIIA. Pediatr Res 60:309\u2013314","journal-title":"Pediatr Res"},{"key":"263_CR73","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/j.ymgme.2007.06.016","volume":"92","author":"AL Roberts","year":"2007","unstructured":"Roberts AL, Rees MH, Klebe S, Fletcher JM, Byers S (2007) Improvement in behaviour after substrate deprivation therapy with rhodamine B in a mouse model of MPS IIIA. Mol Genet Metab 92:115\u2013121","journal-title":"Mol Genet Metab"},{"key":"263_CR74","doi-asserted-by":"crossref","first-page":"2117","DOI":"10.1089\/104303400750001426","volume":"11","author":"CJ Ross","year":"2000","unstructured":"Ross CJ, Bastedo L, Maier SA, Sands MS, Chang PL (2000) Treatment of a lysosomal storage disease, mucopolysaccharidosis VII, with microencapsulated recombinant cells. Hum Gene Ther 11:2117\u20132127","journal-title":"Hum Gene Ther"},{"key":"263_CR75","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.ymgme.2015.10.006","volume":"117","author":"T Ruane","year":"2016","unstructured":"Ruane T, Haskins M, Cheng A, Wang P, Aguirre G, Knox VW, Qi Y, Tompkins T, O\u2019Neill CA (2016) Pharmacodynamics, pharmacokinetics and biodistribution of recombinant human N-acetylgalactosamine 4-sulfatase after 6 months of therapy in cats using different IV infusion durations. Mol Genet Metab 117:157\u2013163","journal-title":"Mol Genet Metab"},{"key":"263_CR76","doi-asserted-by":"crossref","first-page":"837","DOI":"10.1016\/S0022-3476(63)80279-6","volume":"63","author":"S Sanfilippo","year":"1963","unstructured":"Sanfilippo S, Podosin R, Langer LJ et al (1963) Mental retardation associated with acid mucpolysacchariduria (heparin sulfate type). J Pediatr 63:837\u2013838","journal-title":"J Pediatr"},{"key":"263_CR77","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/0002-9394(62)91975-X","volume":"53","author":"HG Scheie","year":"1962","unstructured":"Scheie HG, Hambrick GW Jr, Barness LA (1962) A newly recognized forme fruste of Hurler\u2019s disease (gargoylism). Am J Ophthalmol 53:753\u2013769","journal-title":"Am J Ophthalmol"},{"key":"263_CR78","doi-asserted-by":"crossref","first-page":"e54459","DOI":"10.1371\/journal.pone.0054459","volume":"8","author":"EH Schuchman","year":"2013","unstructured":"Schuchman EH, Ge Y, Lai A, Borisov Y, Faillace M, Eliyahu E, He X, Iatridis J, Vlassara H, Striker G (2013) Pentosan polysulfate: a novel therapy for the mucopolysaccharidoses. PLoS One 8:e54459","journal-title":"PLoS One"},{"key":"263_CR79","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/j.jpeds.2013.01.031","volume":"163","author":"CR Scott","year":"2013","unstructured":"Scott CR, Elliott S, Buroker N, Thomas LI, Keutzer J, Glass M, Gelb MH, Turecek F (2013) Identification of infants at risk for developing Fabry, Pompe, or mucopolysaccharidosis-I from newborn blood spots by tandem mass spectrometry. J Pediatr 163:498\u2013503","journal-title":"J Pediatr"},{"key":"263_CR80","doi-asserted-by":"crossref","first-page":"1938","DOI":"10.1038\/mt.2013.141","volume":"21","author":"A Sergijenko","year":"2013","unstructured":"Sergijenko A, Langford-Smith A, Liao AY, Pickford CE, McDermott J, Nowinski G, Langford-Smith KJ, Merry CL, Jones SA, Wraith JE et al (2013) Myeloid\/Microglial driven autologous hematopoietic stem cell gene therapy corrects a neuronopathic lysosomal disease. Mol Ther 21:1938\u20131949","journal-title":"Mol Ther"},{"key":"263_CR81","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/S0140-6736(16)30374-9","volume":"388","author":"M Sessa","year":"2016","unstructured":"Sessa M, Lorioli L, Fumagalli F, Acquati S, Redaelli D, Baldoli C, Canale S, Lopez ID, Morena F, Calabria A et al (2016) Lentiviral haemopoietic stem-cell gene therapy in early-onset metachromatic leukodystrophy: an ad-hoc analysis of a non-randomised, open-label, phase 1\/2 trial. Lancet 388:476\u2013487","journal-title":"Lancet"},{"key":"263_CR82","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1073\/pnas.0912937107","volume":"107","author":"CM Simonaro","year":"2010","unstructured":"Simonaro CM, Ge Y, Eliyahu E, He X, Jepsen KJ, Schuchman EH (2010) Involvement of the Toll-like receptor 4 pathway and use of TNF-\u03b1 antagonists for treatment of the mucopolysaccharidoses. Proc Natl Acad Sci 107:222\u2013227","journal-title":"Proc Natl Acad Sci"},{"key":"263_CR83","doi-asserted-by":"crossref","first-page":"e0153136","DOI":"10.1371\/journal.pone.0153136","volume":"11","author":"CM Simonaro","year":"2016","unstructured":"Simonaro CM, Tomatsu S, Sikora T, Kubaski F, Frohbergh M, Guevara JM, Wang RY, Vera M, Kang JL, Smith LJ et al (2016) Pentosan polysulfate: oral versus subcutaneous injection in mucopolysaccharidosis type I dogs. PLoS One 11:e0153136","journal-title":"PLoS One"},{"key":"263_CR84","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/S0022-3476(73)80162-3","volume":"82","author":"WS Sly","year":"1973","unstructured":"Sly WS, Quinton BA, McAlister WH, Rimoin DL (1973) Beta glucuronidase deficiency: report of clinical, radiologic, and biochemical features of a new mucopolysaccharidosis. J Pediatr 82:249\u2013257","journal-title":"J Pediatr"},{"key":"263_CR85","doi-asserted-by":"crossref","first-page":"14560","DOI":"10.1074\/jbc.M113.529529","volume":"289","author":"H Suzuki","year":"2014","unstructured":"Suzuki H, Ohto U, Higaki K, Mena-Barragan T, Aguilar-Moncayo M, Ortiz Mellet C, Nanba E, Garcia Fernandez JM, Suzuki Y, Shimizu T (2014) Structural basis of pharmacological chaperoning for human beta-galactosidase. J Biol Chem 289:14560\u201314568","journal-title":"J Biol Chem"},{"key":"263_CR86","doi-asserted-by":"crossref","first-page":"526","DOI":"10.1038\/mt.2012.263","volume":"21","author":"T Takai","year":"2013","unstructured":"Takai T, Higaki K, Aguilar-Moncayo M, Mena-Barragan T, Hirano Y, Yura K, Yu L, Ninomiya H, Garcia-Moreno MI, Sakakibara Y et al (2013) A bicyclic 1-deoxygalactonojirimycin derivative as a novel pharmacological chaperone for GM1 gangliosidosis. Mol Ther 21:526\u2013532","journal-title":"Mol Ther"},{"key":"263_CR87","unstructured":"Takeda (2017) Shire announces top-line results for phase II\/III clinical trial in children with hunter syndrome and cognitive impairment. \nhttps:\/\/www.shire.com\/en\/newsroom\/2017\/december\/wvdwq3"},{"key":"263_CR88","doi-asserted-by":"crossref","first-page":"506","DOI":"10.1089\/hum.2013.238","volume":"25","author":"M Tardieu","year":"2014","unstructured":"Tardieu M, Zerah M, Husson B, de Bournonville S, Deiva K, Adamsbaum C, Vincent F, Hocquemiller M, Broissand C, Furlan V et al (2014) Intracerebral administration of adeno-associated viral vector serotype rh.10 carrying human SGSH and SUMF1 cDNAs in children with mucopolysaccharidosis type IIIA disease: results of a phase I\/II trial. Hum Gene Ther 25:506\u2013516","journal-title":"Hum Gene Ther"},{"key":"263_CR89","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1016\/S1474-4422(17)30169-2","volume":"16","author":"M Tardieu","year":"2017","unstructured":"Tardieu M, Zerah M, Gougeon ML, Ausseil J, de Bournonville S, Husson B, Zafeiriou D, Parenti G, Bourget P, Poirier B et al (2017) Intracerebral gene therapy in children with mucopolysaccharidosis type IIIB syndrome: an uncontrolled phase 1\/2 clinical trial. Lancet Neurol 16:712\u2013720","journal-title":"Lancet Neurol"},{"key":"263_CR90","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.carres.2016.03.020","volume":"429","author":"M Thonhofer","year":"2016","unstructured":"Thonhofer M, Weber P, Gonzalez Santana A, Tysoe C, Fischer R, Pabst BM, Paschke E, Schalli M, Stutz AE, Tschernutter M et al (2016) Synthesis of C-5a-substituted derivatives of 4-epi-isofagomine: notable beta-galactosidase inhibitors and activity promotors of GM1-gangliosidosis related human lysosomal beta-galactosidase mutant R201C. Carbohydr Res 429:71\u201380","journal-title":"Carbohydr Res"},{"key":"263_CR91","doi-asserted-by":"crossref","first-page":"357","DOI":"10.1089\/hum.2014.158","volume":"26","author":"T Wakabayashi","year":"2015","unstructured":"Wakabayashi T, Shimada Y, Akiyama K, Higuchi T, Fukuda T, Kobayashi H, Eto Y, Ida H, Ohashi T (2015) Hematopoietic stem cell gene therapy corrects neuropathic phenotype in murine model of mucopolysaccharidosis type II. Hum Gene Ther 26:357\u2013366","journal-title":"Hum Gene Ther"},{"key":"263_CR92","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1089\/hum.1996.7.4-537","volume":"7","author":"CB Whitley","year":"1996","unstructured":"Whitley CB, McIvor RS, Aronovich EL, Berry SA, Blazar BR, Burger SR, Kersey JH, King RA, Faras AJ, Latchaw RE et al (1996) Retroviral-mediated transfer of the iduronate-2-sulfatase gene into lymphocytes for treatment of mild Hunter syndrome (mucopolysaccharidosis type II). Hum Gene Ther 7:537\u2013549","journal-title":"Hum Gene Ther"},{"key":"263_CR93","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1203\/00006450-198005000-00008","volume":"14","author":"UN Wiesmann","year":"1980","unstructured":"Wiesmann UN, Spycher MA, Meier C, Liebaers I, Herschkowitz N (1980) Prenatal mucopolysaccharidosis II (Hunter): a pathogenetic study. Pediatr Res 14:749\u2013756","journal-title":"Pediatr Res"},{"key":"263_CR94","doi-asserted-by":"crossref","first-page":"e0122453","DOI":"10.1371\/journal.pone.0122453","volume":"10","author":"H Xie","year":"2015","unstructured":"Xie H, Chung JK, Mascelli MA, McCauley TG (2015) Pharmacokinetics and bioavailability of a therapeutic enzyme (idursulfase) in cynomolgus monkeys after intrathecal and intravenous administration. PLoS One 10:e0122453","journal-title":"PLoS One"},{"issue":"Suppl 1","key":"263_CR95","doi-asserted-by":"crossref","first-page":"S53","DOI":"10.1007\/s10545-009-1057-4","volume":"32","author":"S Yano","year":"2009","unstructured":"Yano S, Moseley K, Pavlova Z (2009) Postmortem studies on a patient with mucopolysaccharidosis type I: histopathological findings after one year of enzyme replacement therapy. J Inherit Metab Dis 32(Suppl 1):S53\u2013S57","journal-title":"J Inherit Metab Dis"}],"container-title":["Handbook of Experimental Pharmacology","Pediatric Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/164_2019_263","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,7,15]],"date-time":"2020-07-15T13:12:55Z","timestamp":1594818775000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/164_2019_263"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019]]},"ISBN":["9783030504939","9783030504946"],"references-count":97,"URL":"https:\/\/doi.org\/10.1007\/164_2019_263","relation":{},"ISSN":["0171-2004","1865-0325"],"issn-type":[{"value":"0171-2004","type":"print"},{"value":"1865-0325","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019]]},"assertion":[{"value":"27 August 2019","order":1,"name":"first_online","label":"First Online","group":{"name":"ChapterHistory","label":"Chapter History"}}]}}